Optimal antiplatelet therapy in patients with acute coronary syndrome and chronic kidney disease: for the Jerusalem platelets thrombosis and intervention in cardiology (JUPITER-11) study group
In patients with ACS and CKD, rehospitalization, bleeding and mortality rates were similar in30 days in patients treated with ticagrelor/prasugrel versus clopidogrel. Nevertheless, in patients presenting with STEMI and GFR < 30 ml/min, treatment with ticagrelor/prasugrel was correlated with a lower 1-year mortality rate as compared with clopidogrel treatment with no increase in bleeding rates.
Authors
- Tomer Maller
- M David
- Lior Lupu (ORCID: https://orcid.org/0000-0003-4873-2887)
- Itshak Amsalem (ORCID: https://orcid.org/0000-0003-0294-4534)
- Michael Glikson (ORCID: https://orcid.org/0000-0001-5706-0395)
- Elad Asher (ORCID: https://orcid.org/0000-0003-3381-605X)
- Meir Tabi (ORCID: https://orcid.org/0000-0002-9199-9985)
- Sharon Bruoha (ORCID: https://orcid.org/0000-0002-0282-7533)
- Hezzy Shmueli (ORCID: https://orcid.org/0000-0002-9512-7164)
- Nir Levy
- Rafi Hitter
- Tal Cohen (ORCID: https://orcid.org/0000-0002-1705-3569)
- Perel Nimrod
- Taha Louay
Institutions
- Ben-Gurion University of the Negev (IL)
- Tel Aviv University (IL)
- Hebrew University of Jerusalem (IL)
- Tel Aviv Sourasky Medical Center (IL)
- Soroka Medical Center (IL)
- Shaare Zedek Medical Center (IL)
- Barzilai Medical Center (IL)
- College of Law and Business (IL)
- Alzheimer's Association of Israel (IL)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1186/s12882-025-04227-8
- Citations
- 1
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.39